Fairfield Financial Advisors, LTD Neurocrine Biosciences Inc Transaction History
Fairfield Financial Advisors, LTD
- $294 Billion
- Q3 2024
A detailed history of Fairfield Financial Advisors, LTD transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Fairfield Financial Advisors, LTD holds 100 shares of NBIX stock, worth $13,541. This represents 0.0% of its overall portfolio holdings.
Number of Shares
100
Previous 100
-0.0%
Holding current value
$13,541
Previous $13.8 Million
16.31%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding NBIX
# of Institutions
626Shares Held
94MCall Options Held
632KPut Options Held
621K-
Black Rock Inc. New York, NY14.2MShares$1.92 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$1.35 Billion0.02% of portfolio
-
State Street Corp Boston, MA5.15MShares$697 Million0.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.57MShares$349 Million0.47% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.86MShares$252 Million3.62% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $13B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...